DK2363142T3 - Elastase til åbning af aflukkede biologiske kanaler - Google Patents
Elastase til åbning af aflukkede biologiske kanaler Download PDFInfo
- Publication number
- DK2363142T3 DK2363142T3 DK10180533T DK10180533T DK2363142T3 DK 2363142 T3 DK2363142 T3 DK 2363142T3 DK 10180533 T DK10180533 T DK 10180533T DK 10180533 T DK10180533 T DK 10180533T DK 2363142 T3 DK2363142 T3 DK 2363142T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- elastase
- biological
- patient
- vein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Enzymes And Modification Thereof (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Materials For Medical Uses (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processing Of Meat And Fish (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Claims (24)
1. Sammensætning omfattende en elastase til anvendelse i en fremgangsmåde omfattende lokal administration af sammensætningen direkte til væggen af en biologiske kanal hos en human patient der lider af eller er modtagelig for en sygdom eller lidelse forbundet med aflukning af en biologisk kanal.
2. Sammensætningen ifølge krav 1, hvor elastasen er i en dosis tilstrækkeligt til at forårsage proteolysen af elastin i væggen af den biologiske kanal.
3. Sammensætningen ifølge krav 2, hvor proteolysen af elastin i væggen af den biologiske kanal sker fra ydersiden.
4. Sammensætningen ifølge et hvilket som helst af kravene 1 til 3, hvor elastasen er en pancreatisk elastase.
5. Sammensætningen ifølge et hvilket som helst af kravene 1 til 3, hvor administrationen fører til forstørrelse af diameteren af den biologiske kanal.
6. Sammensætningen ifølge et hvilket som helst af kravene 1 til 5, hvor patienten har behov for hæmodialyse, hvor den biologiske kanal er en arterie eller vene og hvor: (a) administrationen er til, og elastasen er i en dosis der er tilstrækkelig til, at nedsætte sandsynligheden for venøs aflukning hos patienten; eller (b) administrationen er til, og elastasen er i en dosis tilstrækkelig til, at nedsætte sandsynligheden for stenosedannelse hos patienten; eller (c) administrationen er til, og elastasen er i en dosis tilstrækkelig til, at nedsætte sandsynligheden for intima hyperplasi hos patienten.
7. Sammensætningen ifølge krav 6, hvor administrationen er til, og enzymet er i en dosis tilstrækkelig til, at nedsætte sandsynligheden for venøs aflukning hos patienten.
8. Sammensætningen ifølge krav 6, hvor administrationen er til, og enzymet er i en dosis tilstrækkelig til, at nedsætte sandsynligheden for stenosedannelse hos patienten.
9. Sammensætningen ifølge krav 6, hvor administrationen er til, og enzymet er i en dosis tilstrækkelig til, at nedsætte sandsynligheden for intima hyperplasi hos patienten.
10. Sammensætningen ifølge et hvilket som helst af kravene 1 til 9, hvor den biologiske kanal er en arterie.
11. Sammensætningen ifølge et hvilket som helst af kravene 1 til 9, hvor den biologiske kanal er en vene.
12. Sammensætningen ifølge krav 11, hvor fremgangsmåden yderligere omfatter forbindelse af venen til en arterie.
13. Sammensætningen ifølge krav 12, hvor venen er forbundet til arterien via et transplantat.
14. Sammensætningen ifølge krav 11, hvor venen er forbundet til et arteriovenøst hæmodialyse-transplantat.
15. Sammensætningen ifølge et hvilket som helst af kravene 1 til 5, hvor den biologiske kanal er aflukket.
16. Sammensætningen ifølge krav 15, hvor enzymet er i en dosis der gendanner kanalstrømmen.
17. Sammensætningen ifølge krav 15 eller krav 16, hvor den biologiske kanal er en arterie eller vene der er aflukket af intimal hyperplasi.
18. Sammensætningen ifølge krav 15 eller krav 16, hvor den biologiske kanal er en arterie eller vene der er aflukket af stenose.
19. Sammensætningen ifølge krav 18, hvor stenosen tillader passage af et utilstrækkeligt volumen af blod før behandlingen.
20. Sammensætningen ifølge et hvilket som helst af kravene 1 til 5, hvor den humane patient lider af hjertekransaflukning.
21. Sammensætningen ifølge et hvilket som helst af kravene 1 til 20, hvor sammensætningen administreres af et kateter.
22. Sammensætningen ifølge et hvilket som helst af kravene 1 til 20, hvor sammensætningen administreres af en sprøjte.
23. Sammensætningen ifølge et hvilket som helst af kravene 1 til 22, der omfatter elastase og ikke omfatter collagenase.
24. Sammensætningen ifølge et hvilket som helst af kravene 1 til 23, der forlænger passage i den biologiske kanal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15593899P | 1999-09-24 | 1999-09-24 | |
| EP20070008805 EP1923068B1 (en) | 1999-09-24 | 2000-09-24 | Systems and methods for opening obstructed biological conduits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2363142T3 true DK2363142T3 (da) | 2015-04-20 |
Family
ID=22557384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07008805T DK1923068T3 (da) | 1999-09-24 | 2000-09-24 | Systemer og fremgangsmåder til åbning af blokerede biologiske kanaler |
| DK00965396T DK1220830T3 (da) | 1999-09-24 | 2000-09-24 | Anvendelse af elastase til åbning af obstruerede arterier og vener |
| DK10180533T DK2363142T3 (da) | 1999-09-24 | 2000-09-24 | Elastase til åbning af aflukkede biologiske kanaler |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07008805T DK1923068T3 (da) | 1999-09-24 | 2000-09-24 | Systemer og fremgangsmåder til åbning af blokerede biologiske kanaler |
| DK00965396T DK1220830T3 (da) | 1999-09-24 | 2000-09-24 | Anvendelse af elastase til åbning af obstruerede arterier og vener |
Country Status (12)
| Country | Link |
|---|---|
| EP (4) | EP2363142B8 (da) |
| JP (2) | JP5763286B2 (da) |
| AT (2) | ATE511854T1 (da) |
| AU (1) | AU7612100A (da) |
| CA (1) | CA2385488C (da) |
| CY (3) | CY1106656T1 (da) |
| DE (1) | DE60034694T2 (da) |
| DK (3) | DK1923068T3 (da) |
| ES (3) | ES2284528T3 (da) |
| HK (1) | HK1162302A1 (da) |
| PT (3) | PT1923068E (da) |
| WO (1) | WO2001021574A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7063838B1 (en) | 1999-09-24 | 2006-06-20 | Proteon Therapeutics Llc | Methods for treating an artery or vein in a human subject |
| AU2004213050B2 (en) * | 2003-02-20 | 2010-09-09 | Proteon Therapeutics, Inc. | Methods for the treatment and prevention of diseases of biological conduits |
| BRPI0515569A (pt) * | 2004-09-22 | 2008-07-29 | Proteon Therapeutics Inc | métodos para reduzir vasospasmo em um segmento de um conduto biológico, para reduzir a capacidade de um vaso sofrer vasospasmo em um segmento de um conduto biológico e para reduzir o acúmulo de hiperplasia ìntima em um segmento de um conduto biológico |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| US8501449B2 (en) | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
| ES2968836T3 (es) | 2012-01-12 | 2024-05-14 | Endo Global Ventures | Enzima del clostridium histolyticum |
| WO2014066622A2 (en) | 2012-10-24 | 2014-05-01 | The Research Foundation For The State University Of New York | Use of collagenase to treat glaucoma |
| IL301796A (en) | 2017-03-01 | 2023-05-01 | Endo Ventures Ltd | A method for evaluating and treating cellulite |
| WO2018183582A2 (en) | 2017-03-28 | 2018-10-04 | Endo Ventures Limited | Improved method of producing collagenase |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489261A (en) * | 1981-01-26 | 1996-02-06 | Trustees Of Boston University | Hydrogels capable of supporting cell growth |
| US4636195A (en) * | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
| US4803294A (en) * | 1987-10-29 | 1989-02-07 | G. D. Searle & Co. | Process and intermediates for the preparation of halogenated protease inhibitors |
| JPH0286777A (ja) * | 1988-09-22 | 1990-03-27 | Sankyo Co Ltd | サル膵臓エラスターゼｉ |
| US5116615A (en) * | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
| AU5045690A (en) * | 1989-01-27 | 1990-08-24 | Immunolytics, Inc. | Composition and method for treating benign prostatic hypertrophy |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| NL8900943A (nl) * | 1989-04-14 | 1990-11-01 | Euro Biopharm Technology B V | Protease inhibitor. |
| US5318531A (en) * | 1991-06-11 | 1994-06-07 | Cordis Corporation | Infusion balloon catheter |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5422261A (en) * | 1993-04-16 | 1995-06-06 | Baxter International Inc. | Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells |
| US5409926A (en) | 1993-07-19 | 1995-04-25 | Merck & Co., Inc. | AT-2 antagonist inhibition of vascular restenosis |
| ATE354638T1 (de) * | 1994-12-13 | 2007-03-15 | Human Genome Sciences Inc | Menschlicher gewebsinhibitor von metalloproteinase-4 |
| US6020181A (en) * | 1995-05-17 | 2000-02-01 | New York Blood, Inc. | Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase |
| US5830468A (en) * | 1995-05-17 | 1998-11-03 | The New York Blood Center, Inc. | Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase |
| US5834449A (en) * | 1996-06-13 | 1998-11-10 | The Research Foundation Of State University Of New York | Treatment of aortic and vascular aneurysms with tetracycline compounds |
| ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
-
2000
- 2000-09-24 DK DK07008805T patent/DK1923068T3/da active
- 2000-09-24 DE DE2000634694 patent/DE60034694T2/de not_active Expired - Lifetime
- 2000-09-24 DK DK00965396T patent/DK1220830T3/da active
- 2000-09-24 DK DK10180533T patent/DK2363142T3/da active
- 2000-09-24 AT AT07008805T patent/ATE511854T1/de active
- 2000-09-24 CA CA2385488A patent/CA2385488C/en not_active Expired - Fee Related
- 2000-09-24 PT PT07008805T patent/PT1923068E/pt unknown
- 2000-09-24 ES ES00965396T patent/ES2284528T3/es not_active Expired - Lifetime
- 2000-09-24 ES ES10180533.1T patent/ES2534938T3/es not_active Expired - Lifetime
- 2000-09-24 EP EP10180533.1A patent/EP2363142B8/en not_active Expired - Lifetime
- 2000-09-24 WO PCT/US2000/026237 patent/WO2001021574A1/en active IP Right Grant
- 2000-09-24 JP JP2001524955A patent/JP5763286B2/ja not_active Expired - Fee Related
- 2000-09-24 AU AU76121/00A patent/AU7612100A/en not_active Abandoned
- 2000-09-24 EP EP20070008805 patent/EP1923068B1/en not_active Expired - Lifetime
- 2000-09-24 AT AT00965396T patent/ATE361095T1/de active
- 2000-09-24 PT PT101805331T patent/PT2363142E/pt unknown
- 2000-09-24 EP EP20000965396 patent/EP1220830B1/en not_active Expired - Lifetime
- 2000-09-24 ES ES07008805T patent/ES2364191T3/es not_active Expired - Lifetime
- 2000-09-24 EP EP20100183002 patent/EP2332568A1/en not_active Withdrawn
- 2000-09-24 PT PT00965396T patent/PT1220830E/pt unknown
-
2007
- 2007-06-14 CY CY20071100790T patent/CY1106656T1/el unknown
-
2011
- 2011-09-08 CY CY20111100865T patent/CY1112329T1/el unknown
-
2012
- 2012-03-07 HK HK12102287.4A patent/HK1162302A1/xx not_active IP Right Cessation
- 2012-04-04 JP JP2012085454A patent/JP5793461B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-29 CY CY20151100477T patent/CY1117932T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7361335B2 (en) | Methods for using an elastase | |
| JP5793461B2 (ja) | 閉塞した生物学的管を開通するためのシステムと方法 | |
| Welch et al. | Infected false aneurysms in the groin of intravenous drug abusers | |
| US10179163B2 (en) | Methods of treatment with elastase | |
| JPH04501848A (ja) | 血小板依存性動脈血栓症の予防方法 | |
| Simionescu et al. | Chemical stabilization of the extracellular matrix attenuates growth of experimentally induced abdominal aorta aneurysms in a large animal model | |
| JP2007525423A (ja) | 生体導管の疾患を治療および予防するための方法 | |
| Ragnarsson et al. | Microvascular anastomosis of interpositional vein grafts with the UNILINK system: A comparative experimental study | |
| Gu et al. | Toe-to-hand transfer: an analysis of 14 failed cases | |
| Fossali et al. | Percutaneous transluminal renal angioplasty in neurofibromatosis | |
| RU2817988C1 (ru) | Способ восстановления функционального состояния печени при тяжёлом остром панкреатите | |
| RU2222269C2 (ru) | Способ лечения панкреонекроза | |
| Helbing et al. | Infection as a late complication in vascular grafting | |
| Gerard et al. | Hepatic Artery Ligation and Portal Vein Infusion |